| General information | |
| ACovPid: | ACoVP100405 |
| Trivial Name: | Peptide #2 |
| Amino Acids Sequence: | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL |
| Length: | 36 |
| C-Terminal Modification: | None |
| N-Terminal Modification: | None |
| Chemical Modification: | None |
| Peptide Source: | Severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) / Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) / Middle East respiratory syndrome coronavirus (MERS-CoV) : 694009/2697049 |
| Source Description: | From the heptad repeat region 2 of spike protein |
| Against Virus: | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2) : 2697049 |
| Inhibition Value Type: | IC50 |
| Inhibitory Effect: | 1.49 |
| Inhibitory Unit: | µM |
| Target Domain Name: | |
| Assay: | Pseudotyped virus infection inhibition assay |
| Assay Description: | 293T cells were transfected with an expression plasmid for SARS-CoV-2-S, VSV-G, or control expression plasmid by calcium-phosphate precipitation. At 16 h posttransfection, the cells were inoculated with a replication-deficient VSV, VSV-ΔG-Luciferase, which lacks the VSV-G gene and encodes firefly luciferase, at an MOI=1. After 2 h of incubation, cells were washed with DMEM and further incubated for 16 h before supernatants containing the pseudotyped viral particles were harvested. Cellular debris was removed from the supernatants using a syringe filter with a 0.2 µm size pore (Millipore, Bedford, MA, USA).For an infection assay, target Calu-3 cells were seeded in 96-well plates (5×10^4 cells/100 µL) one day before the assay. Cells were pre-treated with peptides for 1 h before infection. Pseudotyped viral particles were added to cells with the peptides. After 2 h of incubation, the culture supernatant was removed, and cells were washed with EMEM. Cells were further incubated in EMEM containing 10% FBS without peptides and pseudotyped viral particles. At 16 h postinfection, luciferase activity was measured using the Bright-Glo Luciferase Assay System (Promega) and Centro xS960 luminometer (Berthold). |
| Anti-CoV activity in vivo: | |
| Reference: | 33424013 |
| Comment: | The concluded sequence for peptide synthesis was generated after alignment of SARS-CoV, SARS-CoV-2, and MERS-CoV HR2 sequences. |
| 3D structure: | |
| Structure Experiment Verified: | NO |
| Similar Peptides: | ACoVP100119 ACoVP100241 ACoVP100125 ACoVP100389 ACoVP100120 |